8ejk: Difference between revisions

No edit summary
No edit summary
 
Line 4: Line 4:
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[8ejk]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8EJK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8EJK FirstGlance]. <br>
<table><tr><td colspan='2'>[[8ejk]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8EJK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8EJK FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2YB:[(3S)-6-({2,6-DIMETHYL-4-[3-(METHYLSULFONYL)PROPOXY]BIPHENYL-3-YL}METHOXY)-2,3-DIHYDRO-1-BENZOFURAN-3-YL]ACETIC+ACID'>2YB</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.4&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2YB:[(3S)-6-({2,6-DIMETHYL-4-[3-(METHYLSULFONYL)PROPOXY]BIPHENYL-3-YL}METHOXY)-2,3-DIHYDRO-1-BENZOFURAN-3-YL]ACETIC+ACID'>2YB</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8ejk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8ejk OCA], [https://pdbe.org/8ejk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8ejk RCSB], [https://www.ebi.ac.uk/pdbsum/8ejk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8ejk ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8ejk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8ejk OCA], [https://pdbe.org/8ejk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8ejk RCSB], [https://www.ebi.ac.uk/pdbsum/8ejk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8ejk ProSAT]</span></td></tr>
</table>
</table>
== Function ==
== Function ==
[https://www.uniprot.org/uniprot/GBB1_HUMAN GBB1_HUMAN] Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction.<ref>PMID:18611381</ref>  
[https://www.uniprot.org/uniprot/GBB1_HUMAN GBB1_HUMAN] Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction.<ref>PMID:18611381</ref>  
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
FFAR1 is a G-protein-coupled receptor (GPCR) that responds to circulating free fatty acids to enhance glucose-stimulated insulin secretion and release of incretin hormones. Due to the glucose-lowering effect of FFAR1 activation, potent agonists for this receptor have been developed for the treatment of diabetes. Previous structural and biochemical studies of FFAR1 showed multiple sites of ligand binding to the inactive state but left the mechanism of fatty acid interaction and receptor activation unknown. We used cryo-electron microscopy to elucidate structures of activated FFAR1 bound to a G(q) mimetic, which were induced either by the endogenous FFA ligand docosahexaenoic acid or gamma-linolenic acid and the agonist drug TAK-875. Our data identify the orthosteric pocket for fatty acids and show how both endogenous hormones and synthetic agonists induce changes in helical packing along the outside of the receptor that propagate to exposure of the G-protein-coupling site. These structures show how FFAR1 functions without the highly conserved "DRY" and "NPXXY" motifs of class A GPCRs and also illustrate how the orthosteric site of a receptor can be bypassed by membrane-embedded drugs to confer full activation of G protein signaling.
Molecular mechanism of fatty acid activation of FFAR1.,Kumari P, Inoue A, Chapman K, Lian P, Rosenbaum DM Proc Natl Acad Sci U S A. 2023 May 30;120(22):e2219569120. doi: , 10.1073/pnas.2219569120. Epub 2023 May 22. PMID:37216523<ref>PMID:37216523</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 8ejk" style="background-color:#fffaf0;"></div>
==See Also==
*[[Transducin 3D structures|Transducin 3D structures]]
== References ==
== References ==
<references/>
<references/>

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA